East Rutherford, NJ - January 18, 2022 - Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
“Today, we welcome our new colleagues from Snapdragon to Cambrex,” said Tom Loewald, CEO of Cambrex. “With Snapdragon’s depth of scientific expertise in API process development, I’m certain our customers will see the benefits of this combination and be delighted to work with Snapdragon’s team.”
“I am extremely proud of what our team at Snapdragon has built over the years,” said Matt Bio, CEO of
Snapdragon. “With Cambrex, we have found an ideal home for our customers and employees, and I look
forward to continued success as part of Cambrex.”
Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.
Cambrex continues to expand its portfolio of specialized solutions for pharmaceutical development and
manufacturing, with Snapdragon bolstering its depth of expertise in continuous flow manufacturing and
complementing recent investments in continuous flow process development capabilities at its High Point,
North Carolina facility.
